Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $33 Price Target
DAY ONE BIOPHARMACEUTICALS, INC. +2.14%
DAY ONE BIOPHARMACEUTICALS, INC. DAWN | 15.76 | +2.14% |
Needham analyst Ami Fadia reiterates Day One Biopharmaceutical (NASDAQ:
DAWN) with a Buy and maintains $33 price target.